Stoke Therapeutics, Inc. (STOK)

Market Cap	1.95B +203.1%
Revenue (ttm)	32.08M -83.2%
Net Income	-169.77M
EPS	-2.81
Shares Out	62.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	614,856
Open	32.83
Previous Close	32.83
Day's Range	30.07 - 33.02
52-Week Range	11.66 - 40.22
Beta	1.18
Analysts	Strong Buy
Price Target	46.00 (+46.59%)
Earnings Date	Aug 11, 2026

About STOK

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2019
• Employees: 170
• Stock Exchange: NASDAQ
• Ticker Symbol: STOK
• Website: https://www.stoketherapeutics.com

Financial Performance

In 2025, Stoke Therapeutics's revenue was $184.42 million, an increase of 404.50% compared to the previous year's $36.56 million. Losses were -$6.89 million, -92.26% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price target is $46.0, which is an increase of 46.59% from the latest price.

Price Target

$46.0

(46.59% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jul 11, 2026

Data Sources Report a data error